semaglutide cardiovascular outcomes study 2025 news Oral and in Patients with Type 2 Diabetes Wegovy confers reductions in cardiovascular

When you introduce semaglutide at the proper beginning dosage, you're essentially teaching your body a new way to handle hunger and satiety

Medicare Part D coverage expansion: The proposed CMS rule allowing Medicare Part D plans to cover anti-obesity medications would make 31 million Medicare beneficiaries with obesity eligible for semaglutide and tirzepatide, representing a USD 55.8 billion annual drug spend potential at 15% initial penetration

Stopping Too Early Tissue repair takes time

however, oral antidiabetic agents hold a leading revenue share in South Korea, with non?insulin injectables (notably GLP?1 receptor agonists) growing fastest due to weight and cardiovascular benefits